About the Company
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GTHX News
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.
G1 Therapeutics files patent for method of treating triple negative breast cancer with CDK4/6 inhibitor
Discover how G1 Therapeutics Inc.'s patent protects healthy cells from chemotherapy damage and treats triple negative breast cancer effectively.
G1 Therapeutics Inc GTHX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options ...
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2023.
G1 Therapeutics Stock (NASDAQ:GTHX), Quotes and News Summary
Follow G1 Therapeutics as it advances trilaciclib in ... Shares of ZoomInfo Technologies Inc. (NASDAQ: ZI) rose sharply in today’s pre-market trading as the company reported stronger-than ...
G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript
Good day, and thank you for standing by. Welcome to the G1 Therapeutics Fourth Quarter 2023 Financial Reference Call. [Operator Instructions] Please be advised that today's conference is being ...
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 ...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options ...
G1 Therapeutics Inc (GTHX)
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with ...
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27. G1 Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of ...
Loading the latest forecasts...